ALAMEDA, Calif.--(BUSINESS WIRE)--Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC) technology for clinical diagnostics and scientific discovery, today outlined a refinement of the Company’s commercial strategy which will expand its Clinical Lab Testing Services direct sales force throughout the United States. In conjunction with this expansion, Singulex also announced the termination of its sales agreement with BlueWave Healthcare Consultants, Inc., an independent contract sales organization.
“As more physicians recognize the clinical value of our SMC™ technology to measure important changes in biomarker levels, demand continues to grow for our SMC™ high value tests. The nationwide expansion of our direct sales force will enable us to provide the best possible support to our growing customer base,” said Guido Baechler, President and Chief Executive Officer of Singulex.
Previously, Singulex’s direct sales coverage was limited to those states in which it did not engage an independent contract sales organization. By deploying additional sales representatives and leveraging its existing support infrastructure, the Company will expand its direct presence across an additional nineteen states in order to provide all its customers with high-quality service.
As part of the refinement of its commercial strategy, Singulex recently hired Anthony Facinelli as Vice President, Clinical Lab Testing Services Sales and Marketing, to lead the commercial growth of the Clinical Lab business. Mr. Facinelli has over twenty years of executive management experience in the clinical lab and diagnostics sectors. Previously, Mr. Facinelli held various executive positions with Quest Diagnostics, including Regional Vice President Sales and senior sales and marketing roles with companies such as Lab Corp, PathNet and Specialty Laboratories.
“Expanding our direct selling efforts across an additional nineteen states where we do not already have an established direct presence, will enable us to better service our customers while growing our business,” said Facinelli.
About Singulex, Inc.
Singulex is the developer and leading provider of Single Molecule Counting (SMC) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC™ technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMCTM technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reacting to disease to proactive health management that also fuels the discovery and development of new therapeutics.
Singulex provides SMC™ technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMCTM technology. Singulex currently is developing the Sgx Clarity™ System, a fully-automated in vitro diagnostics system that will bring the benefits of SMC™ technology to hospital and reference labs worldwide. For further information, please visit www.singulex.com.
